The E3 ubiquitin ligase PARKIN (encoded by PARK2) and the protein kinase PINK1 (encoded by PARK6) are mutated in autosomal-recessive juvenile Parkinsonism (AR-JP) and work together in the disposal of damaged mitochondria by mitophagy 1-3 . PINK1 is stabilized on the outside of depolarized mitochondria and phosphorylates polyubiquitin 4-8 as well as the PARKIN ubiquitin-like (Ubl) domain 9,10 . These phosphorylation events lead to PARKIN recruitment to mitochondria, and activation by an unknown allosteric mechanism 4-12 . Here we present the crystal structure of Pediculus humanus PARKIN in complex with Ser65-phosphorylated ubiquitin (phosphoUb), revealing the molecular basis for PARKIN recruitment and activation. The phosphoUb binding site on PARKIN comprises a conserved phosphate pocket and harbours residues mutated in patients with AR-JP. PhosphoUb binding leads to straightening of a helix in the RING1 domain, and the resulting conformational changes release the Ubl domain from the PARKIN core; this activates PARKIN. Moreover, phosphoUb-mediated Ubl release enhances Ubl phosphorylation by PINK1, leading to conformational changes within the Ubl domain and stabilization of an open, active conformation of PARKIN. We redefine the role of the Ubl domain not only as an inhibitory 13 but also as an activating element that is restrained in inactive PARKIN and released by phosphoUb. Our work opens up new avenues to identify small-molecule PARKIN activators.
The E3 ubiquitin ligase PARKIN (encoded by PARK2) and the protein kinase PINK1 (encoded by PARK6) are mutated in autosomal-recessive juvenile Parkinsonism (AR-JP) and work together in the disposal of damaged mitochondria by mitophagy [1] [2] [3] . PINK1 is stabilized on the outside of depolarized mitochondria and phosphorylates polyubiquitin [4] [5] [6] [7] [8] as well as the PARKIN ubiquitin-like (Ubl) domain 9, 10 . These phosphorylation events lead to PARKIN recruitment to mitochondria, and activation by an unknown allosteric mechanism [4] [5] [6] [7] [8] [9] [10] [11] [12] . Here we present the crystal structure of Pediculus humanus PARKIN in complex with Ser65-phosphorylated ubiquitin (phosphoUb), revealing the molecular basis for PARKIN recruitment and activation. The phosphoUb binding site on PARKIN comprises a conserved phosphate pocket and harbours residues mutated in patients with AR-JP. PhosphoUb binding leads to straightening of a helix in the RING1 domain, and the resulting conformational changes release the Ubl domain from the PARKIN core; this activates PARKIN. Moreover, phosphoUb-mediated Ubl release enhances Ubl phosphorylation by PINK1, leading to conformational changes within the Ubl domain and stabilization of an open, active conformation of PARKIN. We redefine the role of the Ubl domain not only as an inhibitory 13 but also as an activating element that is restrained in inactive PARKIN and released by phosphoUb. Our work opens up new avenues to identify small-molecule PARKIN activators.
The RING-between-RING E3 ligase PARKIN contains a RING1 domain that binds ubiquitin-charged E2 enzymes, and transfers ubiquitin from the E2 to an active site Cys residue in the RING2 domain and subsequently to a substrate. Cytosolic PARKIN exists in an autoinhibited, 'closed' conformation [13] [14] [15] [16] , in which binding to E2 is blocked by the amino-terminal Ubl domain as well as by a 'repressor' element (REP), and access to the RING2 active site Cys is blocked by the unique PARKIN domain (UPD, also known as RING0) (Extended Data Fig. 1 ). PhosphoUb binding and/or PARKIN Ubl phosphorylation are presumed to induce conformational domain rearrangements to activate PARKIN [13] [14] [15] [16] ; however, the mechanism and sequence of events are unclear. Once activated, PARKIN ubiquitinates numerous mitochondrial and cytosolic proteins 17 , eventually triggering mitophagy.
To understand how phosphoUb induces PARKIN activation, we used PINK1-phosphorylated 'ubiquitin suicide probes' 18 that can modify Cys residues near a ubiquitin binding site in vitro 19 (Fig. 1a and Extended Data Fig. 1d ). Probes could not modify a previously crystallized construct of human PARKIN lacking the Ubl domain 14 (HsPARKIN(DUbl), amino acids 137-465) ( Fig. 1b) . Unexpectedly, a similar fragment of Pediculus humanus corporis (human body louse) PARKIN (amino acids 140-461, hereafter referred to as PhPARKIN) was modified by a subset of phosphoUb (pUb) suicide probes ( Fig. 1b) , enabling purification of the PhPARKIN-pUb complex and determination of a crystal structure at 2.6 Å resolution (Fig. 1c Extended Data Figs 1e and 2a). PhPARKIN-pUb resembles autoinhibited structures of HsPARKIN (Fig. 1c, d and Extended Data Fig. 2e ), with key differences as described below. The phosphoUb suicide probe had modified Cys349 in the PhPARKIN in-between-RING (IBR) domain (Figs 1c and 2a), which in HsPARKIN corresponds to probe-unreactive Gln347. Notably, HsPARKIN Q347C is modified by phosphoUb suicide probes ( Fig. 2b) , indicating a similar binding mode of phosphoUb in HsPARKIN. Hence, our complex structure serves as model for phosphoUb binding to HsPARKIN. PhosphoUb forms an extended interface (1,150 Å 2 , 25% of ubiquitin surface) with the RING1 and IBR domains in PhPARKIN, and also interacts with side chains of the UPD ( Fig. 2a and Extended Data Fig. 3 ). Key interactions are formed (1) via the phosphate group, which is located in a pocket formed by His304, Arg307 and Tyr314 of PhPARKIN ( Fig. 2c ); (2) via the hydrophobic Ile44 patch of phosphoUb, which binds to an extended helix in the RING1 domain (amino acids 311-329, hereafter referred to as phosphoUb binding helix (pUBH)); (3) via a conserved surface b-hairpin loop (amino acids 280-288) in RING1 that harbours AR-JP mutations; and (4) via the phosphoUb carboxy terminus, which forms an intermolecular parallel b-sheet with a b-strand of the IBR domain (Figs 1c and 2a f, Activity assays of full-length HsPARKIN variants with and without phosphoUb. After 2 h, reactions were resolved by SDS-PAGE and polyubiquitin visualized by anti-polyubiquitin western blotting (FK2, Millipore). PARKIN protein normalization is shown in Extended Data Fig. 3e . The experiment was performed three times with consistent results. g, YFP-HsPARKIN wild type or mutants were transfected into HeLa cells, treated with CCCP (10 mM) for 1 h and visualized by immunofluorescence. See Extended Data Fig. 4 for controls and quantification. Scale bars, 10 mm. h, HeLa cell lysates expressing YFP-HsPARKIN wild type or mutants were western blotted for PARKIN (after immunoprecipitation (IP)) and Tom20 (in whole-cell lysate (WCL)). NS, nonspecific band. The experiment was performed at least twice as biological replicate for every mutant with consistent results. See Extended Data Fig. 4d and Supplementary Information. Molecular weight markers are in kDa for b, f, h.
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conserved in HsPARKIN (Extended Data Fig. 3a -c), and in our previous HsPARKIN structure 14 the phosphate pocket is occupied by a sulfate molecule from the crystallization condition ( Fig. 2c) .
A fluorescence-polarization-based phosphoUb binding assay revealed sub-micromolar interactions of phosphoUb with full-length HsPARKIN, HsPARKIN(DUbl) and PhPARKIN (Fig. 2d ). Modification with phosphoUb suicide probes of PhPARKIN or HsPARKIN Q347C (HsPARKIN Q347C-pUb) abrogated phosphoUb binding ( Fig. 2d ), indicating that the covalently bound phosphoUb molecule satisfied the major phosphoUb binding site.
Mutations in the predicted phosphoUb interface in HsPARKIN reduced or abrogated phosphoUb binding ( Fig. 2e and Extended Data Fig. 3d ). HsPARKIN K151E (in the phosphate pocket; Fig. 2c , Ala152 in PhPARKIN), A320R (pUBH, Thr322 in PhPARKIN, Fig. 2a ) or G284R (b-hairpin, Gly286 in PhPARKIN, Fig. 2a ) abrogated phosphoUb binding ( Fig. 2e ). HsPARKIN G284R is an AR-JP-derived patient mutation, and our data provide a rationale for how this mutation leads to defects in PARKIN function (see below). Similarly, AR-JP mutation L283P (ref. 20) and cancer-associated H279P (ref. 21) in this region might also disrupt this loop and affect phosphoUb binding to HsPARKIN.
PARKIN activity can be assessed in autoubiquitination assays [4] [5] [6] [7] 14 . HsPARKIN was activated by phosphoUb, whereas HsPARKIN K151E, H302A, A320R or G284R showed impaired phosphoUb-induced activation ( Fig. 2f ). HsPARKIN K161N (an AR-JP mutation on the UPD 14 , see below) and HsPARKIN G319A (see below) bound to and were activated by phosphoUb ( Fig. 2e , f and Extended Data Fig. 3d , e).
In HeLa cells, carbonyl cyanide m-chlorophenyl hydrazone (CCCP)-mediated depolarization of mitochondria led to rapid mitochondrial localization of yellow fluorescent protein (YFP)-tagged HsPARKIN, while phosphoUb-binding mutants did not show mitochondrial localization ( Fig. 2g and Extended Data Fig. 4a -c). Moreover, wild-type HsPARKIN ubiquitinated endogenous Tom20 after CCCP treatment, while phosphoUb-binding mutants showed no apparent activity ( Fig. 2h and Extended Data Fig. 4d ).
Hence, we reveal that the phosphoUb binding site in PARKIN, which is conserved in divergent species, harbours AR-JP patient mutations and is important for PARKIN localization in cells ( Fig. 2) . This provides the molecular basis for PARKIN translocation to mitochondrial phosphoUb 7, 11, 22 (Extended Data Fig. 3g ).
Next we addressed the question of how phosphoUb activates PARKIN. PhosphoUb binds to a straight helix, pUBH, in PhPARKIN (Figs 2 and 3 ). In previous PARKIN structures [14] [15] [16] this helix is kinked at Gly319 (Ala321 in PhPARKIN). The distinct conformation of the pUBH does not originate from this sequence difference; a crystal structure of HsPARKIN(DUbl) G319A still shows a kinked pUBH conformation (Extended Data Figs 1e and 5) and HsPARKIN wild type and G319A have similar biochemical properties ( Fig. 2e , f and Extended Data Fig. 3d, e ). Notably, RING1 of the RBR E3 ligase HHARI (ref. 23 ) also features a kinked helix in the autoinhibited state (see Extended Data Fig. 5e -h). A kinked helix would be unable to bind phosphoUb, leading to a model in which the pUBH is dynamic and straightens upon phosphoUb binding. pUBH straightening hardly affects RING1 (Extended Data Fig. 6a ) but impacts on the position of the IBR domain (Figs 2 and 3a, b), which rotates and moves by .20 Å as compared to full-length rat PARKIN (RnPARKIN) 16 (Fig. 3a ). The conformational change stretches the IBR-REP linker (14-15 amino acids, Extended Data Fig. 2a ) from spanning 31 Å in RnPARKIN to cover a distance of 43 Å in PhPARKIN-pUb ( Fig. 3b and Extended Data Fig. 6b ). This appears to destabilize inhibitory interactions of REP and RING2 as suggested by increased B-factors for these domains in PhPARKIN-pUb (Extended Data Fig. 6c, d ).
More importantly, phosphoUb binding also destabilizes the interface between the PARKIN Ubl domain and the RBR core, due to displacement of the IBR domain and reorganization of the IBR-REP linker that no longer spans the Ubl surface ( Fig. 3b ). Using isothermal titration calorimetry (ITC), we detected binding of isolated HsPARKIN Ubl (amino acids 1-72) to HsPARKIN(DUbl) in trans ( Fig. 3c , dissociation constant (K d ) ,40 mM). Notably, binding is undetectable in the Fig. 2f and Extended Data Fig. 3f ). Experiments were performed three times with consistent results. Molecular weight markers are in kDa.
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presence of phosphoUb, but recovered with phosphoUb-binding-deficient HsPARKIN(DUbl) K151E mutant ( Fig. 3c ). Hence, phosphoUb binding releases the Ubl from the PARKIN RBR core. PARKIN variants lacking the Ubl domain are still autoinhibited [14] [15] [16] and less well activated by phosphoUb in comparison to full-length PARKIN 7 (Fig. 3d ). This indicates that the presence of the Ubl domain is important for full PARKIN activity. Interestingly, replacing the Ubl domain (amino acids 1-79) with SUMO, which lacks a Ubl-like hydrophobic patch and would not bind RING1, activates PARKIN constitutively, even in the absence of phosphoUb. This suggests that the released Ubl domain actively helps to unravel the autoinhibited PARKIN conformation. This, together with destabilization of the REP and RING2 autoinhibitory interactions, enables RING1 to bind and discharge E2-Ub conjugates 4 , and explains how PARKIN is activated by phosphoUb.
An alternative mechanism to activate PARKIN is PINK1-mediated phosphorylation of Ser65 in the Ubl domain 7, 9, 10 , which was also sug-gested to release the Ubl domain from the PARKIN core 9, 24 . In the closed conformation of PARKIN, the Ubl domain binds via its Ile44 patch to RING1 (refs 13, 16) ( Fig. 4a and Extended Data Fig. 1 ). Importantly, PINK1 did not phosphorylate HsPARKIN Ubl I44A (or ubiquitin I44A) efficiently (Extended Data Fig. 7a, b ). This suggests that PARKIN and PINK1 utilize overlapping binding sites on the Ubl domain, and that the Ubl domain has to be released from the PARKIN core for PINK1 to access and phosphorylate it.
Consistently, using a phosphospecific antibody against PARKIN phospho-Ser65 (anti-pSer65 PARKIN), we found that PARKIN phosphorylation is significantly enhanced when phosphoUb is added to the reaction, and this depends on ubiquitin phosphorylation and phosphoUb binding ( Fig. 4c and Extended Data Fig. 7c, d) . Induced release of the Ubl domain by mutating the binding site on RING1 (HsPARKIN L266R, Fig. 4a ) leads to phosphorylation by PINK1 in the absence of phosphoUb ( Fig. 4c and Extended Data Fig. 7c, d 
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indicating that Ubl release is crucial for enhanced phosphorylation. These results reveal a new function for phosphoUb, namely to enable phosphorylation of the Ubl domain ( Fig. 4 ). However, PINK1 can phosphorylate PARKIN in the absence of phosphoUb in vitro (albeit inefficiently, Fig. 4b ) and in cells 7, 25 , showing that PARKIN is a dynamic molecule ( Fig. 4d ) in which the Ubl domain is partially accessible by PINK1.
We next examined consequences of Ubl phosphorylation in HsPARKIN. Nuclear magnetic resonance measurements reveal that the Ubl domain undergoes significant changes when phosphorylated, in particular in the Ser65 loop and the Ile44 patch (Extended Data Fig. 8 ). Disruption of the Ile44 patch prevents re-binding of the Ubl domain to RING1 13, 24 , and probably stabilizes a more open, active conformation of PARKIN. Moreover, this may also explain why the phosphorylated Ubl domain cannot compete with phosphoUb for the phosphoUb binding site (Extended Data Fig. 9 ). Phosphorylated HsPARKIN does not impede binding of phosphoUb, but rather enhances it 7 (Extended Data Fig. 9 ).
Together, this completes our model of PARKIN activation (Fig. 4d ). Autoinhibited PARKIN (Fig. 4d , top left) responds to phosphoUb on mitochondria, which releases the Ubl to activate PARKIN in a reversible manner (Fig. 4d, top row) . PINK1 phosphorylates PARKIN preferentially when the Ubl domain is released (Fig. 4d , bottom middle), and this leads to irreversible PARKIN activation (Fig. 4d, bottom  right) . Alternatively, inactive PARKIN may be phosphorylated by PINK1 directly 7, 25 (Fig. 4d , bottom left); this improves phosphoUb binding, retains PARKIN on mitochondria, and irreversibly activates PARKIN (Fig. 4d, bottom row) .
The conformation of fully active PARKIN remains elusive. Phosphorylated PARKIN but not phosphoUb-activated PARKIN exposes its active site Cys residue 7 (Extended Data Fig. 10 ), further indicating that PARKIN phosphorylation leads to 'opening' of PARKIN. Notably, mutations in a putative second phosphate pocket in the UPD, which we reported previously 14 and which is distinct from the pocket involved in phosphoUb binding, prevents phospho-Ubl-induced PARKIN opening and activation (Extended Data Fig. 10c, d) . The functional link between PARKIN phosphorylation and a putative phosphate-binding pocket in the UPD may suggest that the phosphorylated Ubl domain binds back to the UPD; however, alternative activation mechanisms or the involvement of the Ubl-UPD linker cannot be excluded.
Our work is consistent with suggested models of PARKIN-mediated mitophagy 7,25-28 and provides a structural understanding for phosphoUb binding and allosteric PARKIN activation. We refine the role of the PARKIN Ubl domain as an essential activating element that is restrained in autoinhibited PARKIN. The model ensures tight temporal and spatial regulation of PARKIN activity, and incorporates a commitment step whereby PARKIN phosphorylation locks PARKIN in the active, open conformation. Our insights may prove useful pharmacologically, since small molecules that dislodge the PARKIN Ubl domain from the PARKIN core may activate PARKIN and benefit patients with Parkinson's disease.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. laboratory for reagents and discussions, and D. Barford 
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METHODS
No statistical methods were used to predetermine sample size. Protein expression and purification. HsPARKIN full length, HsPARKIN(DUbl) (amino acids 137-465), PhPARKIN (amino acids 140-461), PhPINK1 (amino acids 115-575) as well as Tribolium castaneum PINK1 (TcPINK1, amino acids 128-570) were expressed as GST fusion proteins in Rosetta2 pLacI cells from pOPIN-K vectors as described 14 Fig. 1e . The HsPARKIN(DUbl) G319A structure was refined with simulated annealing to reduce model bias. Both structures were refined with TLS, using different protein chains as individual TLS groups. Final Ramachandran statistics were 95.3%/4.7%/0.0% (favoured/allowed/outliers) for the HsPARKIN G319A mutant structure, and 96.7%/3.2%/0.1% for the PhPARKIN-pUb structure. Structure figures were generated with PyMol (http://www.pymol.org). Fluorescence polarization phosphoUb binding assays. N-terminally FlAsHtagged ubiquitin was phosphorylated and purified as described for phosphoUb 8 with buffers supplemented with b-mercaptoethanol. Labelling was performed overnight at 4 uC with 60 mM FlAsH-tagged phosphoUb at a ratio of 37.5:1 (v/v) with Lumio Green (Invitrogen) in 1 3 FlAsH dilution buffer (50 mM Tris (pH 7.4), 1 mM b-mercaptoethanol). Buffer exchange was performed with PD-10 desalting columns (GE Healthcare) in 50 mM Tris (pH 7.4), 2 mM b-mercaptoethanol and samples were concentrated to ,8 mM FlAsH-labelled phosphoUb. For binding studies in 384-well low volume plates (Corning), 10 ml of 100 nm labelled phosphoUb was mixed with 10 ml of PARKIN serial dilutions in FlAsH buffer (20 mM Tris (pH 7.4), 100 mM NaCl, 2 mM b-mercaptoethanol, 0.1 mg ml 21 bovine serum albumin). Fluorescence polarization (FP 5 (II 2 IH)/(II 1 IH)) was measured using a PheraStar plate reader (BMB Labtech) with the optic module set to l ex 5 485 nm and l em 5 520 nm. Measurements were performed in triplicate and error bars are given as the standard deviation from the mean. A least square fit for one binding site was performed using the following equation FP~(B max |X=(K d zX))zNS|Xzbackground with FP being fluorescence polarization and X the concentration of the titrant, B max is the maximum specific binding, K d is the equilibrium dissociation constant and NS the slope for nonspecific binding, which was restricted to values greater than 0. PARKIN activity assays. Spin-filtered HsPARKIN (2 mM) was pre-incubated for 0.5 h at 30 uC with 10 mM ATP, 1 3 ligation buffer (40 mM Tris pH 7.5, 10 mM magnesium chloride, 0.6 mM dithiothreitol (DTT)), a total concentration of 0.5 mg ml 21 ubiquitin and 0.05 mg ml 21 phosphoUb or 0.1 mM GST-TcPINK1 where indicated. Ubiquitination was initiated by adding 0.1 mM E1 and 1 mM UBE2L3 ( Fig. 2f and Extended Data Fig. 10d ) or 0.2 mM E1 and 2 mM UBE2L3 (Fig. 3d ). The reaction was quenched with LDS sample buffer containing DTT and iodoacetamide to prevent forming of disulfide bridges. NuPAGE 4-12% gradient Bis-Tris gels were used for separation, and proteins were transferred on a nitrocellulose membrane with subsequent detection using an anti-polyubiquitin FK2 antibody (Millipore). Immunofluorescence. HeLa cells (originating from ATCC) were nucleofected with N-terminally tagged eYFP-HsPARKIN (gift from the J. Kittler laboratory) and grown on coverslips for 24-48 h. After treatment with DMSO or CCCP (10 mM) for 1 h, cells were fixed with 4% paraformaldehyde, washed with 0.1 M glycine in phosphate buffered saline (PBS), at pH 7.4, briefly permeabilized with 0.2% Triton X-100 in PBS and blocked with a blocking solution containing 10% goat serum and 0.5% BSA. Samples were further incubated with anti-Tom20 antibody (FL-145, Santa Cruz) followed by goat Alexa647-coupled anti-rabbit antibody (Life Technologies). Confocal images were taken using a Zeiss LSM780 microscope. Immunoblotting and immunoprecipitation. HeLa cells (originating from ATCC) were transfected with eYFP-HsPARKIN. After 24-48 h, cells were treated with DMSO or CCCP as before, and lysed in cell lysis buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% (v/v) NP-40) supplemented with EDTA-free protease inhibitor cocktail (Roche), PhosphoSTOP (Roche), as well as 10 mM N-ethylmaleimide (Sigma-Aldrich) and 10 mM chloracetamide (Sigma-Aldrich) for better detection of ubiquitinated proteins. For immunoprecipitation of eYFP-HsPARKIN, 500 mg of cell lysate was incubated with GFP-Trap agarose (Chromotek) for 1 h. The beads were washed three times with cell lysis buffer, and proteins were eluted with 1 3 LDS buffer. Cells were regularly checked for the absence of mycoplasma infection using the MycoAlert Kit (Lonza). Antibodies were from commercial sources: goat anti-GFP (ab6673, Abcam), rabbit anti-Tom20 (FL-145, Santa Cruz), mouse anti-GAPDH (6C5, Ambion). Isothermal titration calorimetry. Isothermal titration calorimetry (ITC) experiments were performed in a MicroCal iTC200 machine (GE Healthcare) at 20 uC with the sample and the ligand in low salt buffer. The cell contained 35 mM of LETTER RESEARCH HsPARKIN(DUbl) and 400 mM HsPARKIN Ubl was injected in 2 ml injections at 120 s intervals. Protein sample as well as ligand were in low salt buffer and HsPARKIN(DUbl) was mixed with phosphoUb at a 1:1.2 molar ratio as indicated. Binding curves were integrated and fitted to a one-site binding model by using the MicroCal ITC Analysis plug-in for Origin (Malvern). Phosphorylation assays. PARKIN phosphorylation was performed by incubating 5 mM HsPARKIN with 0.5 mM GST-TcPINK1, 10 mM ATP, 1 3 reaction buffer and phosphoUb (14 mM unless stated differently). The reaction was quenched at the given time points with LDS sample buffer and proteins were separated on a NuPAGE 4-12% gradient Bis-Tris gel, transferred on nitrocellulose membrane and detected with anti-pSer65 PARKIN antibody (Abcam cat no. ab154995). Phosphorylation assays of HsPARKIN Ubl domain (amino acids 1-72) and ubiquitin were performed as described above with 20 mM of HsPARKIN Ubl domain and ubiquitin, respectively. For the ubiquitin phosphorylation assay, the GST-TcPINK1 concentration was increased to 1.5 mM. The reaction was quenched at the given time points with LDS sample buffer and proteins were separated on a 15% SuperSep Phos-tag gel (Wako Chemicals) and stained with Instant Blue SafeStain (Expedeon). Phosphorylation of the PARKIN Ubl domain for NMR analysis. Isotopelabelled HsPARKIN Ubl domain (amino acids 1-72) was expressed in M9 minimal media supplemented with 4 g l 21 13 C-glucose, 2 g l 21 15 N-NH 4 Cl, trace elements and BME vitamins (Sigma-Aldrich) and purified as described above. The final gel filtration was performed in NMR buffer (18 mM Na 2 HPO 4 , 7 mM NaH 2 PO 4 (pH 7.2), 150 mM NaCl, 5 mM TCEP). Isotope-labelled HsPARKIN Ubl was phosphorylated at room temperature by incubating 80 mM HsPARKIN Ubl with 2.5 mM PhPINK1, 1 mM ATP and 1 3 ligation buffer which was adjusted to 332.5 ml with NMR buffer, before addition of 17.5 ml D 2 O as lock solvent. The reaction was monitored by consecutive 1 H, 15 N 2D BEST-TROSY (band selective excitation short transients transverse relaxation optimized spectroscopy) experiments and quenched with apyrase. Solution studies of the phosphorylated PARKIN Ubl domain. NMR acquisition was performed at 298 K on a Bruker Avance III 600 MHz spectrometer equipped with a cryogenic triple resonance TCI probe. The software packages Topspin3.2 (Bruker) and Sparky (Goddard & Kneller, UCSF; http://www.cgl.ucsf. edu/home/sparky/) were used for data processing and analysis, respectively. 1 H, 15 N 2D BEST-TROSY experiments 33 were conducted with in-house optimized Bruker pulse sequences that contained a recycling delay of 400 ms and 512 3 64 complex points in the 1 H, 15 N dimension, respectively.
Standard HSQC-based Bruker triple resonance pulse sequences were used to generate backbone chemical shift assignments. CBCACONH and HNCACB spectra were collected with 50% non-uniform sampling (NUS) of 1,024 3 32 3 55 complex points in the 1 H, 15 N and 13 C dimensions. HNCO and HNCACO experiments were acquired using NUS at a rate of 50% with 1,024 3 32 3 48 complex points in the 1 H, 15 N and 13 C dimensions, respectively. Data set processing was performed with compressed sensing using the MddNMR software package 34 . Weighted chemical shift perturbation calculations were completed using the equation H((D 1 H) 2 4K95 (ref. 16) ) to indicate the position of the E2-Ub on PARKIN RING1. Assuming that E2-Ub adopts a canonical conformation on RING1, the E2 would clash with the Ubl domain and partially with the REP, while the E2-linked ubiquitin would clash with the REP. Hence, Ubl and REP have to be released to enable PARKIN E2-Ub binding at RING1. d, Time-course analysis of an exemplary reaction of UbC3Br (0.2 mg ml 21 ) phosphorylated by GST-PhPINK1 (5 mM) as described previously for ubiquitin 8 . Phosphorylation of proteins was monitored by a band shift on Coomassie-stained Phos-Tag gels. The experiment was performed two times with consistent results. Molecular weight markers are in kDa. e, Data collection and refinement statistics. . 14) ). Red asterisks denote the phospho-Ser65 ubiquitin binding pocket, and yellow spheres the residues contacting phosphoUb (see Fig. 2 ). A black asterisk denotes the catalytic Cys in RING2. b, Stereo representation of the asymmetric unit of PhPARKIN-pUb crystals, showing 2 | F o | 2 | F c | electron density at 1s, in blue for PhPARKIN and in green for phosphoUb. c, Electron density detail, shown as in b, zooming in on phosphoUb phospho-Ser65, in stereo representation. d, Superposition of the two PhPARKIN-pUb complexes in the asymmetric unit, coloured as in Fig. 1 
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Extended Data Figure 4 | PARKIN phosphoUb-binding mutants do not translocate to mitochondria. a, b, HeLa cells that do not contain detectable levels of PARKIN were transiently transfected with YFP-HsPARKIN wild type and indicated mutants (green). Tom20 staining with anti-Tom20 antibody indicates mitochondria (red). Images are representative of three biological replicates. a, In DMSO-treated control cells, PARKIN does not co-localize with mitochondrial Tom20. b, After treatment with CCCP (10 mM) for 1 h, wildtype PARKIN but not phosphoUb-binding mutants co-localize with Tom20. Scale bars, 10 mm. Split channels are shown with overlay to illustrate co-localization. The YFP channel is identical to Fig. 2g . Digital zoom 103. c, Quantification of cells with PARKIN localized at mitochondria in b, scored for 150 cells per condition in three biological replicates. PhosphoUb binding mutants do not show sustained mitochondrial localization. Error bars represent standard error of the mean. d, HeLa cells transiently transfected with HsPARKIN wild type and mutants were treated with CCCP and YFP-HsPARKIN immunoprecipitated (see Methods). Whole-cell lysates (WCL) or immunoprecipitates (IP) were western blotted for PARKIN, Tom20 and GAPDH (loading control) as indicated. Ubiquitinated forms of PARKIN and Tom20 can be observed with wild-type PARKIN but not with PARKIN mutants. See also Fig. 2h where the A320R mutant was also included. These experiments were performed three times as biological replicates with similar results. Note that PARKIN autoubiquitination varied and was weaker in some experiments, while Tom20 ubiquitination was more robust. Molecular weight markers are in kDa. See Supplementary Information for uncropped blots.
Extended Data Figure 6 | Structural detail and B-factor analysis. a, PhosphoUb-induced pUBH straightening is energetically neutral as the two hydrogen bonds between helix residues and the RING1 core are not lost but only adjusted. Left: full-length RnPARKIN structure (PDB 4K95 (ref. 16) ). Right: PhPARKIN-pUb structure. b, Structure of full-length RnPARKIN (PDB 4K95 (ref. 16 ), left), PhPARKIN-pUb (middle), and a superposition of the two (right), in which Ca atoms of structurally identical, ordered residues of the IBR-REP linker are shown as spheres. The distance between these residues is indicated by a dotted line. The linker sequence is highlighted in Extended Data Fig. 2 16)) is not included as in this 6.5 Å structure overall B-factors were assigned. d, Structures of PhPARKIN-pUb are shown as in c for each molecule of the asymmetric unit. The REP and RING2 elements are destabilized as indicated by higher B-factors. The rigid core of the protein has shifted from the UPD-RING1-RING2 interfaces (compare c) to the UPD-RING1-IBR-phosphoUb interfaces. B-factor analysis may be distorted by neighbouring molecules and crystal contacts, which are not indicated here. 1IYF (ref. 36) ). The perturbed residues cluster in the Ser65-containing loop and in proximity to the Ile44 patch of the Ubl. d, Mapping of the perturbed resonances to the structure of RnPARKIN (PDB 4K95 (ref. 16 )) shows that they perturb the interface between the Ubl domain and the PARKIN core. Thus, phosphorylated Ubl may not be able to (re)bind PARKIN at the same binding site.
Extended Data Figure 9 | PARKIN phosphoUbl does not compete with phosphoUb. a, A possible scenario is that the phosphoUbl competes with phosphoUb for the phosphoUb binding site on PARKIN. This could be favoured since the interaction would occur in cis. b, Fluorescence polarization competition experiment increasing the concentration of Ubl, phosphoUbl or phosphoUb with respect to full-length HsPARKIN in the presence of FlAsHtagged phosphoUb. Measurements were performed in triplicate with error bars given as standard deviation from the mean. While unlabelled phosphoUb competes with labelled phosphoUb in the reaction, Ubl or phosphoUbl do not compete with phosphoUb. c, Binding of FlAsH-phosphoUb to HsPARKIN and phospho-HsPARKIN. The measurements were performed in the same experiment as samples in Fig. 2d . If phosphoUbl interacts with HsPARKIN in cis, phosphoUb binding should be inhibited. In contrast, binding of phosphoUb to phospho-PARKIN is slightly enhanced as also reported in ref. 7 . Measurements were performed in triplicate and error bars represent standard deviation from the mean. d, PARKIN phosphorylation assays as in Fig. 4c , including phosphoUbl as well as phosphoUb (both at 10 mM). While addition of phosphoUb induces PARKIN phosphorylation, addition of phosphoUbl does not, indicating that the Ubl domain is not released from the PARKIN core. The experiment has been performed three times with consistent results. Molecular weight markers are in kDa.
